Polyarteritis Nodosa (PAN)

1. Comprehensive Introduction & Overview: Understanding Polyarteritis Nodosa (PAN)

Polyarteritis Nodosa (PAN) is a severe, systemic necrotizing vasculitis that primarily affects medium-sized muscular arteries. Unlike many other forms of vasculitis that involve capillaries or venules (such as ANCA-associated vasculitis), PAN is characterized by focal, segmental transmural inflammation, leading to arterial wall necrosis, aneurysm formation, and subsequent ischemic organ damage.

The Clinical Signature

The term "polyarteritis" refers to the involvement of multiple arteries, while "nodosa" refers to the characteristic nodules that form along the vessel walls due to aneurysmal dilation. Because it typically spares the pulmonary circulation, it is clinically distinct from other systemic vasculitides. PAN can present as a localized cutaneous form (Cutaneous PAN) or a life-threatening systemic disease involving the kidneys, gastrointestinal tract, peripheral nerves, and skin.

2. Deep-Dive: Etiology and Pathophysiology

Etiology and Triggers

While the exact etiology of idiopathic PAN remains elusive, the disease is fundamentally an immune-mediated process. Approximately 10–30% of cases are associated with chronic Hepatitis B virus (HBV) infection, where the deposition of Hepatitis B surface antigen-antibody (HBsAg-anti-HBs) complexes in arterial walls triggers the inflammatory cascade. In the majority of cases, however, PAN is considered idiopathic.

Pathophysiological Mechanisms

The hallmark of PAN is the necrotizing inflammation of the media of medium-sized arteries. The process involves:
1. Immune Complex Deposition: Circulating immune complexes lodge in the arterial wall, particularly at bifurcations.
2. Leukocyte Recruitment: Activation of the complement system attracts neutrophils and macrophages.
3. Fibrinoid Necrosis: The internal elastic lamina is destroyed, leading to the replacement of healthy arterial tissue with fibrinoid material.
4. Aneurysm Formation: The structural integrity of the vessel wall is compromised, resulting in microaneurysms (often visible on angiography).
5. Ischemia and Infarction: The narrowing of the lumen (due to intimal proliferation and thrombus formation) leads to distal organ ischemia.

3. Extensive Clinical Indications & Presentation

PAN is a "great imitator," often presenting with constitutional symptoms that can delay diagnosis.

Standard Clinical Presentation

• Constitutional Symptoms: Unexplained fever, weight loss, night sweats, and profound malaise.
• Dermatological: Livedo reticularis (net-like mottling), subcutaneous nodules, palpable purpura, and digital gangrene.
• Neurological: Mononeuritis multiplex (sudden onset of asymmetric motor and sensory deficits) is highly characteristic.
• Renal: Hypertension (due to renal artery stenosis) and hematuria. Note: Glomerulonephritis is notably absent.
• Gastrointestinal: Post-prandial abdominal pain (intestinal angina) caused by mesenteric ischemia.

Clinical Staging & The Five-Factor Score (FFS)

To prognosticate and guide treatment intensity, the Five-Factor Score (FFS) is frequently utilized:
1. Proteinuria: > 1 g/24h
2. Renal Insufficiency: Serum creatinine > 1.58 mg/dL
3. Gastrointestinal Involvement: Bleeding, infarction, or perforation
4. Cardiomyopathy: Heart failure
5. Central Nervous System Involvement

Each factor present assigns 1 point. A score of 0 indicates a better prognosis, while scores of 1 or higher necessitate aggressive immunosuppressive therapy.

4. Key Diagnostic Tests

Diagnosis requires a high index of suspicion and a combination of clinical, laboratory, and imaging criteria.

Laboratory Markers

• Acute Phase Reactants: Elevated ESR and CRP are universal.
• CBC: Leukocytosis and thrombocytosis (reactive to systemic inflammation).
• Serology: Mandatory screening for Hepatitis B (HBsAg) and Hepatitis C.
• ANCA: Testing is typically negative; if positive, an alternative diagnosis (e.g., GPA or EGPA) should be considered.

Imaging and Biopsy

• Angiography: The gold standard for non-invasive diagnosis. The presence of microaneurysms in the renal, hepatic, or mesenteric arteries is pathognomonic.
• Biopsy: Tissue biopsy (skin, nerve, or muscle) remains the definitive diagnostic tool. It shows necrotizing arteritis with fibrinoid necrosis.

5. Risks, Side Effects, and Contraindications of Treatment

Treatment typically involves high-dose corticosteroids combined with cyclophosphamide for severe cases.

Risks of Standard Immunosuppression

• Corticosteroids: Osteoporosis, hyperglycemia, hypertension, insomnia, and increased risk of opportunistic infections.
• Cyclophosphamide: Hemorrhagic cystitis, bladder cancer, bone marrow suppression (leukopenia), and infertility.
• Antivirals: In HBV-associated PAN, the use of plasma exchange and antivirals (e.g., Lamivudine, Entecavir) is required alongside steroids, but cytotoxic agents are often minimized to avoid worsening the viral load.

Contraindications

Patients with active, severe infections should not receive high-dose immunosuppression until the infection is controlled. In patients with significant renal impairment, the dosage of cyclophosphamide must be adjusted to prevent toxicity.

6. Massive FAQ Section

Q1: Is Polyarteritis Nodosa contagious?

A: No. While Hepatitis B virus infection can trigger PAN, the vasculitis itself is an autoimmune response, not an infectious disease.

Q2: What is the difference between PAN and Microscopic Polyangiitis (MPA)?

A: MPA involves smaller vessels (capillaries) and is frequently ANCA-positive. PAN involves medium-sized arteries and is almost always ANCA-negative.

Q3: Why is pulmonary involvement rare in PAN?

A: The medium-sized arteries affected in PAN are essentially absent in the pulmonary parenchyma, which is why lung involvement is not a feature of this disease.

Q4: Can PAN be cured?

A: With timely diagnosis and aggressive treatment, many patients achieve long-term remission. However, it is a chronic condition that requires lifelong monitoring.

Q5: What is Mononeuritis Multiplex?

A: It is a painful, asymmetric neuropathy caused by the inflammation of the vasa nervorum (the arteries supplying the nerves), leading to nerve ischemia.

Q6: How is Hepatitis B-associated PAN treated differently?

A: It focuses on viral load reduction via antiviral therapy and plasma exchange to remove circulating immune complexes, rather than relying solely on high-dose chemotherapy.

Q7: Are there any specific dietary recommendations?

A: There is no specific "PAN diet." However, patients on steroids must manage salt and sugar intake to control blood pressure and glucose levels.

Q8: What is the significance of Livedo Reticularis?

A: It is a clinical sign of impaired blood flow in the skin. In PAN, it is often painful and can be a precursor to skin ulceration.

Q9: What happens if PAN is left untreated?

A: It is fatal. The disease leads to multi-organ failure, primarily through bowel infarction, renal failure, or cardiac complications.

Q10: Is there a genetic component to PAN?

A: Idiopathic PAN is not typically inherited. However, a related condition called DADA2 (Deficiency of Adenosine Deaminase 2) mimics PAN and has a strong genetic basis.

7. Long-Term Prognosis

The prognosis of PAN has improved dramatically since the introduction of corticosteroid and cyclophosphamide therapy.
* Without treatment: The 5-year survival rate is less than 15%.
* With treatment: The 5-year survival rate exceeds 80%.

Long-Term Management Strategies

1. Monitoring for Relapse: Patients must be monitored for the return of constitutional symptoms or new neurological deficits.
2. Hypertension Control: Essential to prevent renal failure and cardiovascular events.
3. Bone Health: Patients on long-term steroids require Calcium and Vitamin D supplementation, and potentially bisphosphonates.
4. Psychosocial Support: Given the chronic and unpredictable nature of the disease, support groups and psychological care are often beneficial for patient quality of life.

Summary Table: Therapeutic Approach

Disclaimer: This guide is intended for educational purposes for healthcare professionals and clinical students. It does not replace professional medical advice. Always refer to the latest ACR (American College of Rheumatology) or EULAR guidelines for clinical decision-making.